|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500096024 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-16 10:40:41 |
|
注册时间: Date of Registration: |
2025-01-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
早产儿相关并发症风险预测模型的建立与评价 |
|
Public title: |
Establishment and evaluation ofrisk prediction model for preterm infants relatedcomplications |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
早产儿相关并发症风险预测模型的建立与评价 |
|
Scientific title: |
Establishment and evaluation ofrisk prediction model for preterm infants relatedcomplications |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张晓威 |
研究负责人: |
张丽 |
|
Applicant: |
xiaowei zhang |
Study leader: |
li zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 180 0312 3806 |
研究负责人电话:
Study leader's |
+86 131 0312 0545 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xwzhang20@163.com |
研究负责人电子邮件: Study leader's E-mail: |
921312611@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市东城区南门仓5号 |
研究负责人通讯地址: |
北京市东城区南门仓5号 |
|
Applicant address: |
5 Nanmencang, Dongcheng District, Beijing |
Study leader's address: |
5 Nanmencang, Dongcheng District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
100700 |
研究负责人邮政编码: Study leader's postcode: |
100700 |
|
申请人所在单位: |
中国人民解放军总医院第七医学中心 |
||
|
Applicant's institution: |
The Seventh Medical Center of Chinese PLA General Hospital |
||
|
研究负责人所在单位: |
中国人民解放军总医院第七医学中心 |
||
|
Affiliation of the Leader: |
The Seventh Medical Center of Chinese PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
S2024-064-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院第七医学中心医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Seventh Medical Center of Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-14 00:00:00 | ||
|
伦理委员会联系人: |
万雷 |
||
|
Contact Name of the ethic committee: |
lei wan |
||
|
伦理委员会联系地址: |
北京市东城区南门仓5号 |
||
|
Contact Address of the ethic committee: |
5 Nanmencang, Dongcheng District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 66721027 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国人民解放军总医院第七医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
The Seventh Medical Center of Chinese PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市东城区南门仓5号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
5 Nanmencang, Dongcheng District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-financing |
||||||||||||||||||||||
|
研究疾病: |
早产儿及相关并发症 |
||||||||||||||||||||||
|
Target disease: |
Preterm infants and related complications |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
病因学/相关因素研究 |
||||||||||||||||||||||
|
Study type: |
Cause/Relative factors study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1.了解早产儿及相关危重新生儿并发症发生的影响因素及结局,为探索完善危重新生儿一体化管理网络提供依据。 2.了解目前在危重新生儿救护及转运工作中存在的问题及薄弱环节,进而提出改进意见和建议,为制定相关政策提供理论依据。 3.探讨区域内建立并完善危重新生儿转运救治网络,对新生儿救治成功率的增加、新生儿死亡率的减低及医疗技术的提高起到了作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To understand the influencing factors and outcomes of complications in premature infants and related critical neonates, and to provide a basis for exploring and improving the integrated management network of critical neonates. 2. To understand the existing problems and weak links in the rescue and transport of critically ill newborns, and put forward suggestions for improvement, so as to provide theoretical basis for formulating relevant policies. 3. To explore the establishment and improvement of the transport and treatment network of critically ill neonates in the region, which plays a role in the increase of the success rate of neonatal treatment, the reduction of neonatal mortality and the improvement of medical technology. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
早产儿及明确危重新生儿主要转诊指征的。(1)母亲危重妊娠、分娩过程中发生并发症所娩出的新生儿。(2)围产期窒息生命体征不稳定者。(3)呼吸困难,需要进行呼吸管理者。(4)反复呼吸暂停。(5)反复惊厥。(6)各种原因所致的休克。(7)单个或多个脏器功能衰竭。(8)胎龄<34周或极超低出生体重儿。(9)严重酸碱、水电解质平衡及糖代谢紊乱。(10)严重心律失常。(11)严重黄疸需要换血者。(12)严重畸形患儿。(13)各种病因需要外科手术治疗者。(14)其它各种危重病症。(15)虽然病情为非危重,但需要治疗;转出医院无相应治疗能力或治疗条件。 |
||||||||||||||||||||||
|
Inclusion criteria |
The main referral indications of premature infants and critically ill neonates are clear. (1) Newborns born to mothers with severe pregnancy and complications during delivery. (2) unstable vital signs of perinatal asphyxia. (3) dyspnea requiring respiratory management. (4) Recurrent apnea. (5) Recurrent seizures. (6) shock caused by various reasons. (7) single or multiple organ failure. (8) gestational age <34 weeks or very extremely low birth weight infants. (9) severe acid-base, water-electrolyte balance and glucose metabolism disorders. (10) Severe arrhythmia. (11) Severe jaundice requiring exchange transfusion. (12) children with severe malformations. (13) patients with various causes requiring surgical treatment. (14) various other critical diseases. (15) The condition is not critical but requires medical care; The patients were transferred out of the hospital without the corresponding treatment capacity or treatment conditions. |
||||||||||||||||||||||
|
排除标准: |
个案信息缺失严重或者重复个案 |
||||||||||||||||||||||
|
Exclusion criteria: |
Severe case information missing or repeated cases |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-02-01 00:00:00至 To 2025-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-02-01 00:00:00 至 To 2025-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
none |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
通过相关医学中心电子病历系统导出电子数据,并使用Excel2016建立数据库 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic data were exported through the electronic medical record system of the relevant medical center, and Excel2016 was used to establish the database |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |